Severe or unusual symptoms - particularly those involving cardiac, pancreatic, or thyroid concerns - should prompt immediate contact with a healthcare provider
2020;31(11891205):e13
Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
Dose reduction or discontinuation may be necessary if you develop: Persistent, intolerable gastrointestinal symptoms despite supportive measures Acute pancreatitis (discontinue permanently) Severe hypoglycemia, particularly if taking concurrent insulin or sulfonylureas Acute kidney injury or worsening renal function Gallbladder disease symptoms (abdominal pain, jaundice) Diabetic retinopathy complications (particularly with semaglutide) Severe hypersensitivity reactions including anaphylaxis or angioedema Pregnancy or plans for pregnancy (for semaglutide, discontinue at least two months before planned conception
